Dabigatran persistence and adherence in New Zealand: a nationwide retrospective observational study
Although Pradaxa, which is the brand name for
Dabigatran, is available on the market today, the drug has come under significant scrutiny for its possibly dangerous side effects.
FDA Drug Safety Communication: Safety review of post-market reports of serious bleeding events with the anticoagulant Pradaxa (
dabigatran etexilate mesylate), FDA, December 7, 2011
Warfarin users, who were older on average than the other patients and had more co-morbidities, were hospitalized an average of 2 days longer than
dabigatran users and 2.6 days longer than rivaroxaban users.
ICU admissions were consistent among the groups, but warfarin use resulted in 3 days longer in the ICU, on average, than
dabigatran and 2.4 days longer than rivaroxaban.
about Idarucizumab approved as first reversal agent for novel oral anticoagulant
dabigatran
Differential Influence of the Antiretroviral Pharmacokinetic Enhancers Ritonavir and Cobicistat on Intestinal P - Glycoprotein Transport and the Pharmacokinetic / Pharmacodynamic Disposition of
Dabigatran.
Dabigatran, a direct thrombin inhibitor, demonstrates antifibrotic effects on lung fibroblasts.
Dabigatran, a direct thrombin inhibitor, blocks differentiation of normal fibroblasts to a myofibroblast phenotype and demonstrates anti-fibrotic effects on scleroderma lung fibroblasts.